NVAX Insider Trading

Insider Ownership Percentage: 1.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $985,852.80

Novavax Insider Trading History Chart

This chart shows the insider buying and selling history at Novavax by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Novavax Share Price & Price History

Current Price: $6.14
Price Change: Price Increase of +0.14 (2.33%)
As of 04/2/2025 03:46 PM ET

This chart shows the closing price history over time for NVAX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$6.00Closing price on 04/01/25:

Novavax Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Novavax (NASDAQ:NVAX)

53.04% of Novavax stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NVAX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$86Mbought$57MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
Novavax logo
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Read More on Novavax

Today's Range

Now: $6.14
Low: $5.70
High: $6.22

50 Day Range

MA: $8.04
Low: $6.00
High: $9.55

52 Week Range

Now: $6.14
Low: $3.81
High: $23.86

Volume

7,620,206 shs

Average Volume

8,028,806 shs

Market Capitalization

$987.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.92

Who are the company insiders with the largest holdings of Novavax?

Novavax's top insider shareholders include:
  1. James F Young (Director)
  2. Filip Dubovsky (Insider)
  3. Rachel K King (Director)
Learn More about top insider investors at Novavax.